BMS has revealed data from the P-III (KRYSTAL-12) clinical evaluation of Krazati vs SoC chemotherapy alone for the treatment of NSCLC associated with KRASG12C-mutation
The study reached the 1EP demonstrating benefits in PFS and ORR with the drug vs SoC as a 2L treatment of NSCLC without any new safety outcomes. Trial is underway for further evaluation of endpoints incl. OS
Additionally, the company’s sNDA for Krazati + cetuximab received priority review for previously treated KRASG12C-mutated locally advanced or metastatic CRC patients in Feb 2024 with the decision anticipated on Jun 21, 2024
Ref: BMS | Image: BMS
Related Posts:- BMS Reports the US FDA’s Acceptance of sNDA for the Combination of Krazati & Cetuximab with Priority Review to Treat Colorectal Cancer (CRC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
